Gold+
| Address | 262, Gangnam-daero, Gangnam-gu, Seoul, Republic of Korea | ||
|---|---|---|---|
| Telephone | +82-10-3375-7513 | Fax | None |
| Website | https://www.ipsen.com/korea/ | hong-kyu.han@ipsen.com | |
Ipsen’s vision is to be a leading global mid-size biopharmaceutical company, with a focus on transformative medicines in three key therapeutic areas: oncology, rare disease and neuroscience. At Ipsen, we are committed to driving innovation and fostering solutions for the most difficult-to-treat cancers. By focusing on areas of oncology with the highest unmet needs, we seek to improve the lives of people living with cancer, delivering the outcomes which matter most to patients.
1) Treatment of renal cell cancer (1) Monotherapy in patients with advanced renal cell carcinoma previously treated with vascular endothelial growth factor (VEGF) targeted therapy (2) Combination therapy with nivolumab as first-line treatment in patients with advanced renal cell carcinoma 2) Treatment of hepatocellular carcinoma : Treatment of hepatocellular carcinoma previously treated with sorafenib
1) treatment of acromegaly when the circulating levels of growth hormone and IGF-1 remain abnormal after surgery and/or radiotherapy, or in patients who do not respond to therapy with drugs called dopamine agonists. 2) Somatuline Autogel is used for the treatment of symptoms associated with carcinoid syndrome, such as flushing and diarrhoea. 3) Somatuline Autogel is used for the treatment and control of the growth of some advanced tumours of the intestine and pancreas that cannot be removed by surgery (called gastroenteropancreatic neuroendocrine tumours or GEP-NETs).
